Navigation Links
Range of diagnostic spinal fluid tests needed to differentiate concurrent brain diseases
Date:4/20/2012

NEW ORLEANS Teasing out the exact type or types of dementia someone suffers from is no easy task; neurodegenerative brain diseases share common pathology and often co-occur. Researchers from the Perelman School of Medicine at the University of Pennsylvania are continuing efforts to differentiate diseases, such as Alzheimer's disease (AD) from frontotemporal lobar degeneration (FTLD), as FTLD is often clinically difficult to distinguish from atypical presentations of AD.

In a series of studies being presented at the American Academy of Neurology's 64th Annual Meeting in New Orleans, Penn researchers demonstrated that, while tests created for AD are effectively diagnosing the condition when it's clear cut, additional tests are needed to address the many cases with mixed pathology.

"With the emergence of disease-modifying treatments for AD and other neurodegenerative diseases, it will be of utmost importance to accurately identify the underlying neuropathology in patients," said senior author John Q. Trojanowski, MD, PhD, professor of Pathology and Laboratory Medicine and co-director of the Center for Neurodegenerative Disease Research at Penn.

In one study, the Penn team compared results of a test looking at levels of tau and amyloid beta (Aβ) in the spinal fluid, using two different types of analytical platforms. They determined that values from the two platforms could effectively be transformed into equivalent units, and these values accurately distinguished AD from FTLD. A cutoff of 0.34 for the t-tau:Aβ1-42 ratio had 90 - 100 percent sensitivity and 91-96.7 percent specificity to differentiate FTLD cases, respectively.

In another study, the team looked at patient cases with more than one underlying neurodegenerative disease and compared the accuracy of the biomarkers using clinical and neuropathological diagnosis. They determined that cerebral spinal fluid (CSF) Aβ and tau assays provided a valid diagnos
'/>"/>

Contact: Kim Menard
kim.menard@uphs.upenn.edu
215-200-2312
University of Pennsylvania School of Medicine
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Bluestar Silicones Launches a New Range of Silbione(R) TCS 7560 & 7561 Elastomers for Lingerie, Support Stockings and Medical Textile Applications
2. Orange Healthcare Joins the mHealth Alliance to Develop Mobile Health Solutions in West Africa
3. Visual Cues that Improve Walking for People with Movement Disorders - Study Shows Small Change in Arrangement Can Make a Big Difference in Improvement Gained
4. Insightra Medical Inc Gains CE Mark on the Freedom(TM) Inguinal Hernia Product Range
5. Rev. Michel Faulkner Seeks to Retire Charlie Rangel from New York's 15th Congressional Seat
6. New Heart Health Booster Supports Blood Pressure in the Normal Range*
7. Good Bye, Snake Oil! Grab your Orange Juice and Daily Virus Viper™ to Safeguard Against Micro-nutrient Deficiencies
8. Khanna Institute to Offer Newly FDA Approved Expanded Range of Intacs for Keratoconus
9. Strange Artifact Identified as Ancient Anti-Snoring Device
10. HealthCare Partners Medical Group Expands to Orange County. HealthCare Partners and Talbert Medical Group Join Forces
11. Dynowatt Offers Facebook Fans a Chance to See the Rangers and Astros Play for Texas Bragging Rights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... July 31, 2015 , ... ... a novel catheter that was developed for targeted delivery of fluids to selected ... being treated at Florida Hospital Tampa with the device that provides direct, local ...
(Date:7/31/2015)... ... 31, 2015 , ... Ticket Down is a reputable source of authentic ... Soccer Team will face the Australia Women's National Team in two separate friendly contests. ... in Detroit and the second match will occur in Birmingham, Alabama at Legion Field. ...
(Date:7/31/2015)... ... July 31, 2015 , ... Indosoft, Inc., is pleased to ... Q-Suite 5.9. Q-Suite is their flagship contact center ACD system for Asterisk-based call ... display logic shows the script components to the agent only when wanted, and allows ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... a contributor for LeadingAge’s Center for Aging Services Technologies (CAST) Medication Management Technologies ... long-term and post-acute care providers understand the benefits of using medication management ...
(Date:7/31/2015)... Metamora, Michigan (PRWEB) , ... July 31, 2015 ... ... 100th baby at Beaumont Hospital's Karmanos Center for Natural Birth . ... mothers looking for a safe natural childbirth experience. With nurses and caregivers that ...
Breaking Medicine News(10 mins):Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 2Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 3Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 4Health News:Cheap USA vs. Australia Tickets at Legion Field in Birmingham, AL: Ticket Down Slashes Ticket Prices for Australia vs. USWNT at Legion Field 2Health News:Q-Suite 5.9 Adds Validation Tools to Call Center Software Agent Screen 2Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 2Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 3
... Law Requires Certification for Pharmacy Techs, 91% ... Support Standards in Every ... today by the,Pharmacy Technician Certification Board (PTCB) shows that Americans ... prepare prescriptions in pharmacies. The poll results,released today at the ...
... As companies transform their,call centers into service-to-sales operations, ... while maintaining a customer service,function. Because they play ... is one of the key factors behind a ... leaders recommend reducing spans of control by as,much ...
... Are you taking the proper steps,to ward off colds ... so, you could,win a trip to Orlando. The Florida ... healthy this season with the Stay Well. Play,Well. Florida ... should submit a 300-word essay describing their,best kept secrets ...
... State University has received a $5.7 million federal grant ... continue the development of community partnerships that strengthen families ... problems. , The new award will support PROSPER ... additional five years. The total award to Penn State ...
... panel to add it to list of ,probable, causes of ... on the night shifts at bars, convenience stores, hospitals and ... cancer. , That,s the conclusion of an international group of ... official list of "probable" carcinogens. , A team of scientists ...
... 5 Allos,Therapeutics, Inc. (Nasdaq: ALTH ), ... of small molecule therapeutics for,the treatment of cancer, ... will participate on the "Better Drugs & Novel ... Capital Markets Healthcare Conference in New,York., The ...
Cached Medicine News:Health News:Survey Shows Broad Support Among Americans for Pharmacy Technician Certification 2Health News:Managing the Service-to-Sales Cultural Transformation - Complimentary Excerpt Available from Best Practices 2Health News:Escape the Cold and Flu Season With a Free Vacation to the Sunshine State 2Health News:PSU $5.7 million grant to help families and youth avoid substance abuse, behavior problems 2Health News:Night Shift Work May Heighten Risk for Cancer 2Health News:Night Shift Work May Heighten Risk for Cancer 3Health News:Allos Therapeutics to Present at the 2007 RBC Capital Markets Healthcare Conference 2
(Date:7/30/2015)...  Amgen (NASDAQ: AMGN ) today announced ... Key results include: , Total revenues increased ... to $5,370 million, with 6 percent product sales ... Prolia ® (denosumab), Sensipar ® (cinacalcet), ... (denosumab). Unfavorable changes in foreign exchange rates impacted ...
(Date:7/30/2015)... July 30, 2015 Eisai Inc. announced today ... the United States , European Union and ... MHLW, respectively) for eribulin, for the treatment of patients ... prior chemotherapy for advanced or metastatic disease. ... a pivotal global Phase 3 clinical trial (Study 309), ...
(Date:7/30/2015)... Japan , July 30, 2015 ... of the study to fulfill the post-marketing commitment ... the Pan European Multi-Database Bladder Cancer Risk ... retrospective matched cohort study, conducted in four European ... HCI) with up to 10 years of follow-up. ...
Breaking Medicine Technology:Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 2Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 3Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 4Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 5Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 6
... DIEGO, March 21, 2012  Millennium Laboratories announced today ... the course for more responsible and ethical business ... outlines the principles to which Millennium adheres and ... in the pain management industry to adopt. ...
... encourages continuous electronic monitoring, including the use of both ... analgesia (PCA). According to the Institute ... knowledge exist today to prevent errors associated with use ... says , "The solutions are available. We know ...
Cached Medicine Technology:Millennium Laboratories Announces Laboratory Responsibility Pledge 2Millennium Laboratories Announces Laboratory Responsibility Pledge 3Physician-Patient Alliance for Health & Safety: Hospitals Need to Address PCA Pump Patient Safety 2
... IMMULITE 2500 is a high-throughput immunoassay ... ,of the IMMULITE 2000 with the important ... technology ,allows assays to be designed for ... times. ,This allows for critical assays such ...
... sulfate (DHEA-S) is the sulfate ester of ... enzymatic conversion of DHEA in adrenal and ... steroid secreted by the adrenal cortex, and ... biosynthesis. DHEA possesses relatively weak androgenic activity, ...
... DSL's unique DHEA-S-7kits ... antiserum targeted against the ... DHEA-S molecule, with no ... DHEA-S Saliva RIA has ...
... is based on the competition principle and ... DHEA-S present in the sample and a ... peroxidase compete for the binding sites of ... wells. After one hour incubation the microtiterplate ...
Medicine Products: